RA
LPCN icon

Royce & Associates’s Lipocine LPCN Stock Holding History

Royce & Associates’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-8,365
Closed -$489K – 1269
2017
Q4 		$489K Sell
8,365
-41,232
-83% -$2.56M ﹤0.01% 1043
2017
Q3 		$3.35M Sell
49,597
-19,739
-28% -$1.43M 0.02% 702
2017
Q2 		$4.74M Hold
69,336
– – 0.03% 605
2017
Q1 		$4.6M Hold
69,336
– – 0.03% 603
2016
Q4 		$4.34M Buy
69,336
+2,830
+4% +$179K 0.03% 623
2016
Q3 		$5.04M Buy
66,506
+27,937
+72% +$1.73M 0.03% 591
2016
Q2 		$1.99M Sell
38,569
-10,805
-22% -$1.67M 0.01% 809
2016
Q1 		$8.52M Buy
49,374
+1,126
+2% +$192K 0.05% 440
2015
Q4 		$10.6M Sell
48,248
-11,642
-19% -$2.44M 0.06% 391
2015
Q3 		$12M Buy
59,890
+44,176
+281% +$10.2M 0.06% 392
2015
Q2 		$2.29M Buy
15,714
+4,412
+39% +$548K 0.01% 912
2015
Q1 		$1.33M Buy
11,302
+167
+1% +$18.2K 0.01% 997
2014
Q4 		$996K Buy
+11,135
New +$941K ﹤0.01% 1074

Other funds holding LPCN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Royce & Associates's LPCN Position: Q1 2018 in Review

Royce & Associates sold out of Lipocine (LPCN) in Q1 2018, closing a stake of 8,365 shares — an estimated $489K sold.

Royce & Associates first reported a position in LPCN in Q4 2014 and held it in 13 quarters. The position peaked at $12M in Q3 2015. 27 funds tracked by Wall St. Rank hold LPCN as of Q1 2018.

  • Royce & Associates reported no remaining Lipocine position as of Q1 2018 after selling out during the quarter.
  • Royce & Associates sold 8,365 Lipocine shares in Q1 2018, an estimated $489K.
  • Royce & Associates first reported a position in Lipocine in Q4 2014 and held it in 13 quarters.
  • Royce & Associates's Lipocine position peaked at $12M in Q3 2015.
  • 27 funds tracked by Wall St. Rank held Lipocine as of Q1 2018.

Based on Royce & Associates's 13F filing for Q1 2018, filed 14 May 2018.